The effects of DU 1.5 mg and Glar were compared in patients with T2D at 52 weeks from the AWARD-2 study with prevalent elevations in fasting glucose (FG), postprandial glucose… Click to show full abstract
The effects of DU 1.5 mg and Glar were compared in patients with T2D at 52 weeks from the AWARD-2 study with prevalent elevations in fasting glucose (FG), postprandial glucose (PPG), or both FG and PPG at baseline. Changes in glycated hemoglobin (A1c), FG, PPG, body weight, and hypoglycemia were investigated.
               
Click one of the above tabs to view related content.